← boardnext 2026-12
DMAC
DiaMedica Therapeutics Incdistress 2/10 · well-funded / low risk$6.84-1%today-27% from 52w high
Lead: Acute Stroke
Revenue
pre-revenue
Liquidity
$52M
Runway
1.7 yrs
Shares 1y
+4%
Price & events
-17.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.4%
1D
-4.1%
1W
+8.9%
1M
+10.0%
3M
-19.6%
6M
+32.8%
1Y
+98.8%
2Y
+85.4%
5Y
-31.9%
All
Overview
- Market Cap
- $368.56M
- Volume
- 6.06K
- 52 Week Range
- $3.63 – $9.39
- Total Shares
- 53.88M
- Float Shares
- 28.77M
- Short %
- 14.40%
- % Held by Insiders
- 27.74%
- % Held by Institutions
- 37.85%
- RVOL
- 0.03x
- Beta
- 0.97
Pipeline stages · 1 programs
Recombinant human tissue kallikrein
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12 Estimated 50% readout ~2027-02-14 | Phase 2/3 | Recombinant human tissue kallikrein | Acute Stroke, Ischemic Stroke, Stroke | — | recruiting |
Catalyst news & presentations · 2
- 2026-08-11earningsEarningsEarnings releaseyahoo
- second quarter of 2026readoutDM199 · Results from 10-day modified EFD and PPND study in rabbit modelSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $16 (+127% upside) · 4 analysts
- 2025-11-14Cantor FitzgeraldOverweight
- 2025-08-15HC Wainwright & Co.Buy
- 2025-07-18Craig-HallumBuy
- 2025-07-18Lake StreetBuy
- 2025-07-18HC Wainwright & Co.Buy
- 2025-05-29HC Wainwright & Co.Buy
Competitors — Acute Stroke
- none identified
Recent news
- 2026-07-23Price to book forward of DiaMedica Therapeutics Inc. – NASDAQ:DMAC - TradingView
- 2026-07-19$7.37 | DiaMedica Therapeutics Inc. Common Stock (DMAC) Stock Price Today - Binance
- 2026-07-17DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
- 2026-07-17New DiaMedica hire gets 160,000 stock options at $7.64 - Stock Titan
- 2026-07-15(DMAC) Risk Channels and Responsive Allocation - Stock Traders Daily
- 2026-07-06DMAC Q1 2026 Earnings: EPS Misses Estimates as Clinical Pipeline Advances - Earnings Growth Forecast - dars.gov.et
- 2026-06-25DMAC Forecast — Price Target — Prediction for 2027 - TradingView
- 2026-06-24DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction - BioSpace
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.